Authors

Dirk Schadendorf, MD, Essen University Hospital

Latest:

Dr. Schadendorf on Expected Toxicities With Encorafenib/Binimetinib/Pembrolizumab in BRAF V600E/K-Mutated Melanoma

Dirk Schadendorf, MD, discusses expected toxicities with the combination of encorafenib, binimetinib, and pembrolizumab in BRAF V600E/K-mutated melanoma.

Atrayee Basu-Mallick, MD

Latest:

Dr. Basu-Mallick on Established and Emerging Biomarker-Directed Therapies in CRC

Atrayee Basu-Mallick, MD, highlights established and emerging biomarker-directed therapies in colorectal cancer.

Joyce O'Shaughnessy, MD, Baylor-Sammons Cancer Center

Latest:

PI3K Inhibitors for PIK3CA-Mutated HR+ MBC

Considerations for treating patients with HR+/HER2- metastatic breast cancer with alpelisib, a PI3K inhibitor, following frontline treatment with a CDK4/6 inhibitor.

Chatrick Paul, SVP, Head of US Oncology Business, AstraZeneca

Latest:

Our Path Forward in Leading a Revolution in Cancer Care

Chatrick Paul of AstraZeneca shares his perspective on the mission to eradicate cancer as a leading cause of death

Gilberto Lopes, MD, University of Miami Health System

Latest:

Review of AENEAS Trial and Similar Agents

Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.

Sean Collins, MD, PhD

Latest:

Optimizing Care of Patients With Advanced Prostate Cancer: Conclusion

Summarizes the main points and benefits of multidisciplinary prostate cancer care.

Hackensack Meridian John Theurer Cancer Center

Latest:

Hackensack Meridian Health Partners with DELFI Diagnostics, Supported by a Grant from Lilly to Improve Lung Cancer Screening Adherence With Innovative Blood Test

The initiative aims to increase uptake of life-saving LDCT scans for high-risk individuals in line with guidance via a minimally invasive blood test.

Ezra Rosen, MD, PhD

Latest:

Dr Rosen on the Activity of Zotatifin Plus Abemaciclib/Fulvestrant in ER+ Breast Cancer

Ezra Rosen, MD, PhD, discusses the investigation of the triplet combination of zotatifin, abemaciclib, and fulvestrant in a phase 1/2 trial in heavily pretreated patients with estrogen receptor-positive metastatic breast cancer.

Sponsored Content by EMD Serono

Latest:

Extending Overall Survival in Patients with Advanced Urothelial Carcinoma

Stephen L. Chan, MBBS, MD, FACP, MRCP, FHKCP, FHKAM

Gilead Sciences, Inc.

Latest:

ADC Cast: ADC antigen targets: What are we aiming at?

This is a featured episode from an educational podcast series with expert discussions on antibody drug conjugates, intended for US healthcare professionals.

Philip Philip, MD

Latest:

Dr Philip on Considerations for Selecting First-Line Treatment in Newly Diagnosed, Low-Risk GI NETs

Philip Philip, MD, discusses considerations for selecting first-line treatment for newly diagnosed, low-risk gastrointestinal neuroendocrine tumors.

Joshua Reuss, MD, Georgetown Lombardi Comprehensive Cancer Center

Latest:

Charting the Future: Key Therapies for Managing EGFR-Mutant NSCLC

This episode focuses on exploring additional therapeutic options for managing previously treated advanced or metastatic EGFR-mutated NSCLC, highlighting strategies to optimize patient survival across various stages of disease progression.

Amy Jones, MD

Latest:

Dr. Jones on Future Research Efforts in Pancreatic Cancer

Amy Jones, MD, discusses future research efforts in pancreatic cancer.

Nosha Farhadfar, MD

Latest:

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Giovanni Marconi, MD

Latest:

Dr Marconi on the Investigation of Tamibarotene Plus Azacitidine in Higher-risk MDS

Giovanni Marconi, MD, discusses ongoing research with the combination of tamibarotene and azacitidine in patients with higher-risk myelodysplastic syndrome.

Sam Klempner, MD

Latest:

Key Takeaways and Future Questions in Perioperative GC/GEJC

Panelists discuss the key takeaways, including the establishment of durvalumab plus FLOT as the new standard requiring proper laparoscopic staging and multidisciplinary care. Future questions focus on optimizing treatment for nonresponders and developing more personalized therapeutic approaches.

Brian Henick, MD

Latest:

Dr Henick on the Use of Neoadjuvant Atezolizumab Plus Chemotherapy in NSCLC

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

Benjamin Herzberg, MD

Benjamin Herzberg, MD, is an assistant professor of medicine at Columbia University Medical Center and an oncologist at Herbert Irving Comprehensive Cancer Center in New York, New York

Latest:

Dr Herzberg on Management Challenges in STK11/KEAP1+, SMARCA4-Deficient Undifferentiated Tumors and NUT Carcinoma

Benjamin Herzberg, MD, discusses the management challenges associated with STK11/KEAP1-mutated tumors, SMARCA4-deficient undifferentiated tumors, and NUT carcinoma.

Nausheen Ahmed, MD

Latest:

Dr Ahmed on a Study of Real-World Outcomes With Brexu-Cel in Relapsed/Refractory MCL

Nausheen Ahmed, MD, discusses the rationale and design of a subgroup analysis of real-world outcomes with brexucabtagene autoleucel in patients with relapsed/refractory mantle cell lymphoma.